drugset / Trial / NCT07408089
Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a first-in-human, open-label, Phase 1 study evaluating BBI-940, an investigational kinesin oral molecular degrader, administered as monotherapy or in combination with fulvestrant in adults with advanced or metastatic breast cancer.
Timeline
- Start
- 2026-02-25
- Primary completion
- 2029-02-28
- Completion
- 2029-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BBI-940 | Small molecule | — | Oral |
| Background | Fulvestrant | Small molecule | — | Intramuscular |